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patients were biologic-experienced, and 52 (34%) were biologic-naïve before initi-
ating golimumab. A higher percentage of female patients were in the bio-experi-
enced category (70% vs. 55%). Osteoarthritis (27%), hypertension (24%), dyslipide-
mia (17%), and depressive disorders (14%) were the most common comorbidities
prior to the start of golimumab. A higher rate of depressive disorder was observed
in the biologic-experienced group. Baseline mean C-reactive protein test values
were also higher in the biologic-experienced group (3.69 vs. 0.97). Biologic-experi-
enced patients on golimumabwere switchedmostly from adalimumab (n42) and
etanercept (n25). CONCLUSIONS: In this longitudinal EMR, patients receiving
golimumab were more likely to have prior biologic experience. Biologic-experi-
enced patients appeared to have higher C-reactive protein test values and greater
rates of depressive disorders than their biologic-naïve counterparts.
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OBJECTIVES: Golimumab (GLM) is a monthly self-injected anti-tumor necrosis fac-
tor alpha therapy providing once-monthly dosing for patients with rheumatoid
arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). This study
assesses the baseline characteristics and utilization patterns of patients who re-
ceived GLM. METHODS: We performed a retrospective database analysis of The
MarketScan® Research Database from Thomson Reuters. This database contains
individual-level, de-identified, healthcare claims information from employers,
health plans, hospitals, Medicare, and Medicaid. A total of 29,774 patients in this
database had a diagnosis of either RA, PsA or AS and at least one biologic on record
and met the following inclusion criteria: 18 years of age at the time of the first
diagnosis. From this sample, a total of 174 patients had at least one prescription
record for GLM. RESULTS: A total of 174 patients receiving GLM were identified as
meeting all the inclusion criteria; with 128 (RA), 30 (PSA), and 16 (AS). Themean age
was 48 years and 75% of the sample was female. A total of 155 (89%) patients were
bio-experienced and 19 (11%)were bio-naïve before initiating golimumab. A total of
111 patients received at least two GLMdoses. Of the patients with two ormore GLM
doses, the median and mean SD dosing interval was 29.5 days and 33.65  15.56
days. When looking at biologic naïve patients the median and mean SD dosing
interval was 30 days and 35.37  17.63 days versus biologic experienced patients
with a dosing interval of 29 days and 33.15  15.00 days. CONCLUSIONS: In the
MarketScan database, the majority of patients with a prescription for GLM was
female and had prior biologic experience. GLM median and mean doses were 29.5
and 33.37 days respectively. Previous biologics experience did not significantly
change the GLM dosing patterns.
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OBJECTIVES: Golimumab, a newer anti-tumor necrosis factor agent used in patients
with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has recom-
mendeddosing of 50mgoncemonthly. The objective of this studywas to describe the
biologic experience and dosing for patients using golimumab in the managed care
setting. METHODS: The IMS LifeLink™ Health Plan database (100 managed care
plans) was utilized to identify patients aged 18 years at index and having an index
golimumab pharmacy claim started between 4/24/2009 (product approval) and 10/31/
2009. Patients were required to have 24 months pre- and  2 months post-index
continuous enrollment with 1 RA, PsA, or AS ICD-9 diagnosis code. Biologic experi-
encewas assessed for the pre-index period. Dosingwas assessed through end of data
or loss of enrollment. RESULTS: A total of 282 patients receiving golimumab were
identified; 72%were female;meanagewas52years.Themajority (73%) of patientshad
pre-index biologic experience. Among the biologic-experienced, 60% received 1
unique biologic, 33% received 2 unique biologics, and 7% received 3 unique biologics
before golimumab. Golimumabpatients had experiencewith various combinations of
abatacept, adalimumab, certolizumab, etanercept, and infliximab.Adalimumabalone
and etanercept aloneweremost frequently used prior to golimumab. The golimumab
dose at each of the first six prescription fills was 50 mg for over 97% of patients. The
mean (median) days between fills spanned 29-33 (29-30) days. CONCLUSIONS: The
majority ofpatients receivinggolimumabwerebiologic-experienced.Observeddosing
was consistent with prescribing recommendations. Consistency in dosing was ob-
served over the first six prescriptions. Despite the history of biologic use, golimumab
patientsdidnothaveanapparent increaseddose requirementupon initiation. Further
research is necessary to confirm these findings in a larger sample size over a longer
duration of follow-up.
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OBJECTIVES: To understand the reasons for initiating an intravenous (IV) biologic
therapy among prior subcutaneous injection (SQ) users, and patient satisfaction
before and after switching.METHODS: Semi-structured telephone interviewswere
conducted with 405 immunology patients currently receiving IV biologic therapy.
Patients rated their level of satisfaction with current or prior medication on a
7-point Likert scale (7Very satisfied; 1not at all satisfied) and reported reasons
for switching from SQ therapy. RESULTS: More than a third (37%) of surveyed IV
biologic patients previously used SQ administration. Of these patients, overall
mean satisfaction with SQ was 3.8, with 32% rating the SQ experience as a 1 or 2.
Current IV satisfaction ratings among prior SQ users was 6.2 (vs. 6.1 for all patients
surveyed). Of prior SQ users, 26% did not self-administer their injections, most
frequently due to: dislike of needles; lack of confidence in own ability to administer
the injection correctly; and/or physical inability to handle the syringe. Of thosewho
did not self-administer SQ, 39% went to a physician’s office for administration.
Primary reasons for switching from SQ to IV administration included lack of effi-
cacy (81%), side effects (21%), cost (10%) and dislike of self injections (9%).
CONCLUSIONS: In this analysis, current IV biologic users appear highly satisfied
with this medication. Dissatisfied SQ users that did not self-administer may offset
potential “convenience” advantages of a SQ. They also switched to IV mostly for
loss of efficacy and appear to be satisfied with an IV. Given the potential for patient
preference differences, there appears a need for expanded treatment choices. In-
volving the patient in shared decision making and providing access to both IV and
SQ modes of administration may be important to optimizing patient satisfaction.
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OBJECTIVES: To evaluate treatment patterns when different definitions of discontin-
uation are used. Anti-tumor necrosis factor therapies including adalimumab (ADA),
etanercept (ETA) and infliximab (IFX) are used to treat rheumatoid arthritis (RA). Ex-
amining discontinuation rates can help understanding of real-world treatment pat-
terns. Different definitions of discontinuation rates have been reported elsewhere.
METHODS: Data between 01/2005-06/2006 were extracted from the i3Innovus data-
base. Inclusion criteria were aged18,1 claim for RA, and no evidence of pre-index
biologic use in the sixmonths prior. Patients were followed for 24months. Discontin-
uationwasdefinedasagap in therapy60or365days following the lastdayssupply.
RESULTS: Total of 1,780 patientswere analyzed: ADA 601 (33.8%); ETA 785 (44.1%);
IFX394 (22.1%). If discontinuationwas defined as a gap in therapy of60 days, 57.2%
of patients treated with ADA discontinued, 57.5% of patients treated with ETA and
37.6% of IFX patients discontinued. If discontinuationwas defined as a gap in therapy
of 365 days, 22.5% of ADA patients discontinued, 17.3% of ETA patients and 18% of
IFX patients discontinued. Of those defined as ‘discontinuers’ after a gap of therapy of
60 days, 49.7 % of ADA patients, 62.1% of ETA patients and 12.8% of IFX patients
restarted their index therapy on average 146.8, 146.5, and 302.4 days from the time of
defined ‘discontinuation’. Significantly fewer IFX patients restarted their index ther-
apy (P0.0001) and the time from defined discontinuation to restart was longer
(p0.0001). CONCLUSIONS: This analysis demonstrates that different discontinua-
tion rates are observed when different definitions of discontinuation are employed.
This may impact the understanding of real-world prescribing patterns. The data also
suggests that patients treated with ADA and ETA experience lengthy gaps in therapy.
Future research is needed to examine gaps in therapy on clinical andhealth economic
outcomes.
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OBJECTIVES: Prior etanercept drug utilization studies have reported, that among
patients with a gap in observed refill time exceeding the recommended refill time,
31%-44%of patients experienced gaps greater than 2weeks.Mean gaps (assessed at
each individual refill period) ranged from 19 to 37 days. Limited comparative data
exist for infliximab. The objective of this modeling analysis was to assess the
impact on drug levels from gaps in prescription refill behavior that may result in
under-dosing. METHODS: Steady state concentration models for etanercept and
infliximab were developed to simulate the effect of missed dosing (i.e., gap in
etanercept prescription refill or infliximab administration interval). Results were
expressed as a percent of steady state trough levels (SSTL) in g/mL, and were
presented to simulate gaps that varied from 1-5 weeks. Population pharmacoki-
netic models for etanercept and infliximab were used to simulate out steady state
concentration profiles. The parameters used in these models were extracted from
recent publications. RESULTS: After a refill or administration gap of one week,
etanercept and infliximab concentrations were at 13% and 73% of SSTL respec-
tively. At two weeks, SSTL were 4% and 55% respectively. Etanercept levels were
effectively non-existent after three weeks, whereas infliximab was at 40% of SSTL.
Clinical implications were not simulated. CONCLUSIONS: SSTL of etanercept de-
clines rapidly with gaps in refills and disappears with gaps as short as three weeks.
Infliximab demonstrates a muchmore gradual decline. Poor patient refill behavior
may have consequences that go beyond declining drug levels, and patient adher-
ence risk should be an integral part of any discussion during shared treatment
decision making.
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